Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DK132077-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
Not provided
Not provided
Not provided
Not provided
Dietary intake of fruits and vegetables (F&V) is a cornerstone for the treatment of type 2 diabetes, however less than 16% of Hispanic adults consume the recommended number of servings each day. F&V prescription (F&V Rx) programs are embedded into clinical settings and provide patients with vouchers to purchase F&V at local retailers. The proposed study aims to test the effects of a F&V Rx on diabetes self-management education and support (DSME/S) uptake and retention, dietary intake of F&V and diet quality, glucose control (hemoglobin A1c), and program implementation outcomes.
Consuming a nutrient-dense diet, rich in fruits and vegetables (F&Vs) is at the cornerstone of type 2 diabetes (T2DM) treatment. Yet, among Hispanic adults, only 16% meet the recommended minimum F&V intake recommendations and have higher rates of T2DM than non-Hispanic whites (16.6% versus 13.3%, respectively). F&V Prescription (F&V Rx) programs are embedded in clinical settings, target medically high-risk patients such as those with T2DM, and provide them with vouchers to purchase F&V at local retailers. Preliminary F&V Rx studies in patients with T2DM have found F&V intake increases of 0.2-1.6 servings per day and hemoglobin A1c (A1c) reductions from 0.35-0.71% [3.8 -7.8 mmol/mol]. However, none of these studies included diabetes self-management education and support (DSME/S) which can lead to A1c decreases from 0.24% to 1.0% [2.6-10.9 mmol/mol]. The team conducted a pilot F&V Rx study where DSME/S attendance was incentivized by providing a F&V Rx at each session. Although DSME/S uptake is typically very low after referral (around 5-7%), the program had a 73% first session attendance rate. Further, at 7 months post-program, a clinically- and statistically-significant reduction was found in A1c of 1.3% [14.2 mmol/mol] (p=.001). Although the receipt of the F&V Rx vouchers was contingent upon DSME/S attendance in the study, other T2DM-focused F&V Rx studies did not have DSME/S attendance requirements and also saw A1c reductions. Thus, understanding the effect of a F&V Rx on DSME/S uptake and retention with and without attendance requirements is a key design issue that must be evaluated. This proposal is in response to PAS 20-160 for short-term, pilot randomized controlled trials (RCTs) to acquire preliminary data regarding trial design. The team proposes a 3-Arm, 16-week, pilot RCT (n=120) for low-income adults (aged 18+) with T2DM (A1c >7% [53 mmol/mol]). The control group (n=40) will receive usual care (UC). The two intervention groups (n=40 each) will receive UC plus a F&V Rx that is either independent of DSME/S attendance (F&V Rx alone) or dependent on DSME/S attendance (F&V Rx + DSME/S). First, the investigators will systematically explore the impact of a F&V Rx on uptake and retention in DSME/S. Next, the investigators will explore changes in A1c, and diet-related outcomes. Finally, with implementation in mind, the investigators will use Proctor's implementation taxonomy, and the cultural adaptation framework from Castro et al., to assess program appropriateness, acceptability, and sustainability with both participants and clinical care providers. The study team and the Community Advisory Board (CAB) have the research, clinical expertise, and established retail network necessary to conduct a F&V Rx trial in a low-income, Hispanic community. The findings of this trial will inform the design of a future, fully powered RCT and address gaps in knowledge related to how F&V Rx programs impact T2DM-related outcomes. If effective, F&V Rx programs have the potential to improve diabetes self-management and reduce the clinical burden of poor glycemic control, particularly in low-income, Hispanic communities.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Usual Care Control Group | Placebo Comparator | Will receive usual care |
|
| F&V Rx Alone Group | Active Comparator | Will receive 4 monthly F&V Rx vouchers regardless of their DSME/S attendance. |
|
| F&V Rx + DSME/S Group | Active Comparator | Will receive monthly F&V Rx vouchers starting at the first group session and they will receive additional F&V Rx vouchers only when they attend a monthly DSME/S group (up to 4 total) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Usual Care | Behavioral | Visit with a primary care provider and referral for diabetes self-management education and support (DSME/S) sessions |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the impact of a F&V Rx on DSME/S uptake in low-income adults | Defined as the number of participants who attend any 1 DSME (# attend any 1 DSME/S session/total # randomized) | Throughout the 16 week intervention |
| Evaluate the impact of a F&V Rx on DSME/S retention in low-income adults. | Defined as % who attend >=75% of sessions (# attend >= 75% sessions/ # attended any 1 DSME/S session) | Throughout the 16 week intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the impact of a F&V Rx on A1c (% and mg/dL) | Blood biomarker assessment will be taken and analyzed by the Penn State Health Clinical Labs. | Baseline (week 0) and follow up (week 16) |
| Evaluate the impact of a F&V Rx on Diabetes Self-Management |
| Measure | Description | Time Frame |
|---|---|---|
| Assess program implementation outcomes - Acceptability of Intervention Measure (AIM) | A four-item measure implementation outcomes to assess acceptability of the DSME/S sessions and the overall intervention for participants. | Throughout the 16 week intervention and follow-up |
| Assess program implementation outcomes - Intervention Appropriateness Measure (IAM) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Susan Veldheer, DEd, RD | Contact | 717-531-5625 | sveldheer@pennstatehealth.psu.edu | |
| Kayla N Rutt, MS | Contact | 717-858-6204 | krutt1@pennstatehealth.psu.edu |
| Name | Affiliation | Role |
|---|---|---|
| Susan Veldheer, DEd, RD | Penn State College of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Penn State Health St. Joseph Downtown Campus | Recruiting | Reading | Pennsylvania | 19601 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D048909 | Diabetes Complications |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| F&V Rx alone | Behavioral | Usual Care plus four F&V prescriptions that are independent of DSME/S attendance |
|
| F&V Rx plus DSME/S | Behavioral | Usual Care plus four F&V prescriptions that are dependent on DSME/S attendance |
|
Measured by DSME questionnaire |
| Baseline (week 0) and follow up (week 16) |
| Evaluate the impact of a F&V Rx on Fruit and Vegetable Intake | Based on the 24-hour recalls | Baseline (week 0) and follow up (week 16) |
| Evaluate the impact of a F&V Rx on Healthy Eating index-2015 | Based on the 24-hour recalls | Baseline (week 0) and follow up (week 16) |
| Evaluate the impact of a F&V Rx on Total plasma carotenoids (ng/mL) | Plasma carotenoids will be separated into the total and five individual concentrations (α-carotene, β-carotene, lutein, lycopene, and cryptoxanthin) using high-performance liquid chromatography methodology using our Sciex Exion LC-Sciex QTRAP 6500+ mass spectrometry system. | Baseline (week 0) and follow up (week 16) |
| Evaluate the impact of a F&V Rx on Food insecurity | Measured by the 18-item USDA Food Insecurity Questionnaire | Baseline (week 0) and follow up (week 16) |
A four-item measure of implementation to assess the appropriateness of the DSME/S sessions and the overall intervention for participants. |
| Throughout the 16 week intervention and follow-up |
| Assess program implementation outcomes - Clinic/providers/staff - Implementation Outcomes Questionnaire (IOQ) | Survey that measures implementation success of the intervention from the perspective of stakeholders who carry out the daily operations | Throughout the 16 week intervention and follow-up |